Matrix metalloprotease-9, placental syncytiotrophoblast and the endothelial dysfunction of pre-eclampsia
- PMID: 12495663
- DOI: 10.1053/plac.2002.0871
Matrix metalloprotease-9, placental syncytiotrophoblast and the endothelial dysfunction of pre-eclampsia
Abstract
The maternal syndrome of pre-eclampsia is caused by generalized maternal endothelial cell dysfunction, arising directly or indirectly from factors of placental origin. Syncytiotrophoblast membrane microvesicular particles are shed from the placental surface into maternal blood in increased amounts in pre-eclampsia and, in vitro, both inhibit endothelial cell proliferation and cause marked changes in the morphology of the cultured cell monolayers. Because there is evidence that proteolytic activation and degradation of the underlying matrix can cause the same morphological changes, we tested the hypothesis that proteases intrinsic to syncytiotrophoblast microvillous membranes (STBM) are the cause of the in vitro endothelial changes. Purified STBM were analysed by zymography and western blotting. Although we could confirm the presence of urokinase plasminogen activator (uPA) in STBM we could demonstrate no intrinsic activity presumably because of its association with the plasminogen activator inhibitor-2 (PAI-2) which is also a component of STBM. We detected gelatinase activity and showed that it was due to the matrix metalloproteinase-9 (MMP-9). Its presence was confirmed in this location by immunohistocytochemistry. Protease inhibitors caused a small reversal of the effects of STBM on morphology and no effect on inhibition of proliferation. We conclude that the effect of STBM on endothelial cells is unlikely to be caused by intrinsic proteases.
Similar articles
-
Purification and characterization of a complex from placental syncytiotrophoblast microvillous membranes which inhibits the proliferation of human umbilical vein endothelial cells.Placenta. 1999 Jan;20(1):71-9. doi: 10.1053/plac.1998.0351. Placenta. 1999. PMID: 9950147
-
Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies.Br J Obstet Gynaecol. 1998 Jun;105(6):632-40. doi: 10.1111/j.1471-0528.1998.tb10178.x. Br J Obstet Gynaecol. 1998. PMID: 9647154
-
A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells.Placenta. 2005 Jan;26(1):59-66. doi: 10.1016/j.placenta.2004.04.004. Placenta. 2005. PMID: 15664412
-
Effect of syncytiotrophoblast microvillous membrane treatment on gene expression in human umbilical vein endothelial cells.BJOG. 2006 Nov;113(11):1270-9. doi: 10.1111/j.1471-0528.2006.01061.x. BJOG. 2006. PMID: 17059391
-
The functions of microparticles in pre-eclampsia.Semin Thromb Hemost. 2011 Mar;37(2):146-52. doi: 10.1055/s-0030-1270342. Epub 2011 Mar 2. Semin Thromb Hemost. 2011. PMID: 21370216 Review.
Cited by
-
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Adv Pharmacol. 2018;81:241-330. doi: 10.1016/bs.apha.2017.08.002. Epub 2017 Sep 19. Adv Pharmacol. 2018. PMID: 29310800 Free PMC article. Review.
-
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Exp Suppl. 2012;103:209-79. doi: 10.1007/978-3-0348-0364-9_7. Exp Suppl. 2012. PMID: 22642194 Free PMC article. Review.
-
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.Biochem Pharmacol. 2008 Jan 15;75(2):346-59. doi: 10.1016/j.bcp.2007.07.004. Epub 2007 Jul 7. Biochem Pharmacol. 2008. PMID: 17678629 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous